Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effec...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2021-11-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/27/11/21-1886_article |
| _version_ | 1818905937859051520 |
|---|---|
| author | Aharona Glatman-Freedman Yael Hershkovitz Zalman Kaufman Rita Dichtiar Lital Keinan-Boker Michal Bromberg |
| author_facet | Aharona Glatman-Freedman Yael Hershkovitz Zalman Kaufman Rita Dichtiar Lital Keinan-Boker Michal Bromberg |
| author_sort | Aharona Glatman-Freedman |
| collection | DOAJ |
| description | In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting. |
| first_indexed | 2024-12-19T21:31:16Z |
| format | Article |
| id | doaj.art-656803623c2d4b36bb25ec3068ed8471 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-19T21:31:16Z |
| publishDate | 2021-11-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-656803623c2d4b36bb25ec3068ed84712022-12-21T20:04:55ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592021-11-0127112919292210.3201/eid2711.211886Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021Aharona Glatman-FreedmanYael HershkovitzZalman KaufmanRita DichtiarLital Keinan-BokerMichal BrombergIn Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.https://wwwnc.cdc.gov/eid/article/27/11/21-1886_article2019 novel coronavirus diseasecoronavirus diseaseCOVID-19severe acute respiratory syndrome coronavirus 2SARS-CoV-2viruses |
| spellingShingle | Aharona Glatman-Freedman Yael Hershkovitz Zalman Kaufman Rita Dichtiar Lital Keinan-Boker Michal Bromberg Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 Emerging Infectious Diseases 2019 novel coronavirus disease coronavirus disease COVID-19 severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 viruses |
| title | Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 |
| title_full | Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 |
| title_fullStr | Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 |
| title_full_unstemmed | Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 |
| title_short | Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 |
| title_sort | effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars cov 2 delta variant infection israel 2021 |
| topic | 2019 novel coronavirus disease coronavirus disease COVID-19 severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 viruses |
| url | https://wwwnc.cdc.gov/eid/article/27/11/21-1886_article |
| work_keys_str_mv | AT aharonaglatmanfreedman effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 AT yaelhershkovitz effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 AT zalmankaufman effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 AT ritadichtiar effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 AT litalkeinanboker effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 AT michalbromberg effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021 |